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MCP-1/CCR2 system is involved in high glucose-induced fibronectin
and type IV collagen expression in cultured mesangial cells. Am J
Physiol Renal Physiol 295: F749–F757, 2008. First published June
25, 2008; doi:10.1152/ajprenal.00547.2007.—Monocyte chemoat-
tractant protein-1 (MCP-1) is a potent chemokine that plays an
important role in the recruitment of macrophages. Although previous
studies have demonstrated the importance of MCP-1 in the pathogen-
esis of diabetic nephropathy (DN) in terms of inflammation, the role
of MCP-1 and its receptor (C-C chemokine receptor 2; CCR2) in
extracellular matrix (ECM) accumulation under diabetic conditions
has been largely unexplored. This study was undertaken to investigate
the functional role of the MCP-1/CCR2 system in high glucose-
induced ECM (fibronectin and type IV collagen) protein expression in
cultured mesangial cells (MCs). Mouse MCs were exposed to medium
containing 5.6 mM glucose (NG), NG24.4 mM mannitol (NGM),
or 30 mM glucose (HG) with or without mutant MCP-1 (mMCP-1),
CCR2 small interfering (si)RNA, or CCR2 inhibitor (RS102895). To
examine the relationship between MCP-1 and transforming growth
factor (TGF)-1, MCs were also treated with TGF-1 (2 ng/ml) with
or without mMCP-1 or CCR2 siRNA. Transient transfection was
performed with Lipofectamine 2000 for 24 h. Cell viability was
determined by an MTT assay, mouse and human MCP-1 and TGF-1
levels by ELISA, and CCR2 and ECM protein expression by Western
blotting. Transfections of mMCP-1 and CCR2 siRNA increased
human MCP-1 levels and inhibited CCR2 expression, respectively.
HG-induced ECM protein expression and TGF-1 levels were signif-
icantly attenuated by mMCP-1, CCR2 siRNA, and RS102895 (P 
0.05). MCP-1 directly increased ECM protein expression, and this
increase was inhibited by an anti-TGF-1 antibody. In addition,
TGF-1-induced ECM protein expression was significantly abrogated
by the inhibition of the MCP-1/CCR2 system (P  0.05). These
results suggest that an interaction between the MCP-1/CCR2 system
and TGF-1 may contribute to ECM accumulation in DN.
diabetic nephropathy; monocyte chemoattractant protein-1; trans-
forming growth factor-1; extracellular matrix
MONOCYTES/MACROPHAGES ARE the principle inflammatory cells
found in the diabetic kidney (6, 9, 29). These cells are ex-
travasculated from the bloodstream through a process mediated
by chemokines secreted from resident glomerular cells. Che-
mokines are a family of chemotactic cytokines that induce the
migration of various cell types, and to date 40 chemokines
have been identified (31). Among them, monocyte chemoat-
tractant protein (MCP)-1 is the most extensively studied che-
mokine. In the kidney, MCP-1 is expressed in mesangial cells
(MCs) and tubular epithelial cells (22, 26) and is known to be
involved in the pathogenesis of various renal diseases, includ-
ing diabetic nephropathy. Previous studies have demonstrated
that plasma MCP-1 levels are increased in type 1 diabetes with
microalbuminuria (4) and that urinary levels of MCP-1 are also
increased in accordance with the extent of albuminuria (1, 20).
In addition, it has been reported that glomerular MCP-1 ex-
pression is increased in experimental diabetic rats and that this
increase is associated with the number of infiltrated monocytes
in the glomeruli (5, 6). Moreover, an angiotensin-converting
enzyme inhibitor, angiotensin II type 1 receptor blocker, and
aldosterone antagonist all ameliorate glomerular injury in ex-
perimental diabetic animals via the inhibition of MCP-1 ex-
pression and macrophage infiltration (13, 17). Taken together,
these findings suggest that MCP-1 plays a critical role in the
pathogenesis of diabetic nephropathy via inducing inflamma-
tory cell infiltration.
On the other hand, several studies have demonstrated that
cultured MCs express C-C chemokine receptor 2 (CCR2) (10,
16), a receptor of MCP-1, suggesting that MCP-1 may act
directly on these renal cells. Recently, Giunti et al. (10) have
shown that MCP-1 induces concentration-dependent ICAM-1
expression in cultured MCs, implying that MCP-1 may further
increase the inflammatory response by increasing adhesion
molecule expression. In addition, some investigators have
provided evidence that MCP-1 may be directly involved in
extracellular matrix (ECM) synthesis, using animal models of
experimental glomerulonephritis and diabetic nephropathy (11,
30, 36). To our knowledge, however, there has not been a study
that has looked at the functional role of the MCP-1/CCR2
system in high glucose-induced ECM protein expression. In
this study, we investigated the role of the MCP-1/CCR2 system
in high glucose-induced fibronectin and type IV collagen
expression and the relationship between the MCP-1/CCR2
system and TGF-1 in cultured MCs.
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MATERIALS AND METHODS
Cell cultures. Mouse MCs from an SV40 transgenic mouse (MES-
13) were purchased from American Type Culture Collection (Man-
assas, VA) and maintained in DMEM (Invitrogen, Gaithersburg, MD)
containing 5% FBS (Invitrogen). MCs were maintained and incubated
at 37°C in humidified 5% CO2 in air.
Inhibition of MCP-1/CCR2 system. In this study, three different
methods were utilized to block the MCP-1/CCR2 system in cultured
MCs. First, mutant MCP-1 (mMCP-1) was used to competitively
inhibit native MCP-1 action. The mMCP-1 gene was constructed by
a recombinant PCR using a wild-type human MCP-1 cDNA from
human peritoneal mesothelial cells as a template, which was then
cloned into the BamHI (5) and XhoI (3) sites of the eukaryotic
expression vector plasmid cDNA3 (Invitrogen) as described previ-
ously (40). Second, predesigned mouse CCR2 small interfering
(si)RNA was purchased from Ambion (Austin, TX). The mMCP-1
gene and CCR2 siRNA were transfected with Lipofectamine 2000
(Invitrogen) according to the manufacturer’s protocol. Briefly, 6 l of
Lipofectamine 2000 was diluted in 1 ml of Opti-MEM I Reduced
Serum Medium (Invitrogen), incubated for 15 min at room tempera-
ture, and mixed with a variable amount of mMCP-1 (final concentra-
tions: 0.5 and 1.0 g/ml) and CCR2 siRNA (final concentrations: 10,
25, and 50 nM). After 15-min incubation at room temperature, the
mixture was added to each well of MCs, which were plated at a
density of 5  105 cells/well into six-well plates the day before, and
the medium was changed after 24 h. Last, RS102895 (final concen-
trations: 1 and 10 M, Sigma, St., Louis, MO), a specific chemical
inhibitor of CCR2, was also used.
Transfected MCs were serum restricted for 24 h, after which the
medium was replaced by serum-free DMEM containing normal glu-
cose (NG; 5.6 mM), NGmannitol (NGM; 24.4 mM), or high
glucose (HG; 30 mM). In addition, nontransfected MCs were cultured
under NG, NGM, or HG with or without RS102895 or anti-TGF-1
antibody (25 g/ml). Nontransfected MCs were also exposed to
medium containing recombinant human MCP-1 (10 ng/ml, R&D
Systems, Minneapolis, MN) or recombinant human TGF-1 (2 ng/ml,
R&D Systems). At 24 h after the media change, cells were harvested
and the conditioned culture media were collected.
Methylthiazoletetrazolium assay. To examine the cytotoxicity of
the agents used in this study, MCs were cultured in 96-well culture
plates, phenol red-free DMEM with 1 mg/ml of methylthiazoletetra-
zolium (MTT) added to each well after the experimental periods, and
then incubated for 2 h at 37°C in humidified 5% CO2 in air. Extraction
buffer (20% SDS, 50% N,N-dimethylformamide, pH 4.7) was added
to the wells, which were further incubated overnight at 37°C. Optical
density (OD) was measured with a microplate reader (SpectraMax
340, Molecular Devices) at a wavelength of 562 nm. The OD of the
NG cells was assigned a relative value of 100. The experiments were
performed in triplicate.
ELISA. The levels of secreted MCP-1 and TGF-1 under different
experimental conditions were determined with conditioned culture
media using commercial ELISA kits (R&D Systems) according to the
manufacturer’s protocol, and each protein level was normalized with
cell numbers. The experiments were performed in triplicate.
The kits for mouse and human MCP-1 were species specific and
sensitive up to 2.0 and 5.0 pg/ml, respectively. On the other hand, the
minimum sensitivity for mouse TGF-1 of the kit used in this study
was 4.6 pg/ml.
Western blot analysis. Harvested MCs lysed in SDS sample buffer
[2% SDS, 10 mM Tris HCl, pH 6.8, 10% (vol/vol) glycerol] were
Fig. 1. Human (A) and mouse (B) monocyte chemoattractant protein-1
(MCP-1) levels, assessed by ELISA, in mMCP-1-transfected mouse mesangial
cells (n  5). In mutant (m)MCP-1-transfected cells, human MCP-1 levels
were significantly increased in a dose-dependent manner, while there was no
difference in the levels of mouse MCP-1, suggesting that mMCP-1 was
efficiently transfected. Transfection of an empty vector had no effects on the
levels of mouse and human MCP-1. *P  0.0001 vs. control.
Fig. 2. C-C chemokine receptor 2 (CCR2) protein expression, assessed by
Western blotting, in CCR2 small interfering (si)RNA-transfected mouse mes-
angial cells (n  5). CCR2 protein expression was significantly decreased in
CCR2 siRNA-transfected cells in a dose-dependent manner, suggesting that
transfected CCR2 siRNA efficiently inhibited the native expression of CCR2.
In contrast, a negative control of CCR2 siRNA had no effect on CCR2 protein
expression. *P  0.05 vs. control.
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used for CCR2, fibronectin, and type IV collagen protein expression.
The samples were treated with Laemmli sample buffer, heated at
100°C for 5 min, and electrophoresed in a 10% acrylamide denaturing
SDS-polyacrylamide gel. Proteins were then transferred to a Hybond-
ECL membrane using a Hoeffer semidry blotting apparatus (Hoeffer
Instruments, San Francisco, CA). The membrane was then incubated
in blocking buffer A (1 PBS, 0.1% Tween 20, and 8% nonfat milk)
for 1 h at room temperature, followed by an overnight incubation at
4°C in a 1:1,000 dilution of polyclonal antibodies to CCR2, fibronec-
tin, type IV collagen, or -actin (Santa Cruz Biotechnology, Santa
Fig. 3. A: fibronectin and type IV collagen protein expression, assessed by Western blotting, in mouse mesangial cells exposed to 10 ng/ml MCP-1 (n  5).
Administration of 10 ng/ml MCP-1 significantly increased the protein expression of fibronectin in cultured mesangial cells, and this increase in fibronectin
expression was significantly ameliorated by the inhibition of CCR2 with 10 nM CCR2 siRNA (siRNA) or 10 M RS102895 (RS). *P  0.05 vs. other groups.
B–D: fibronectin and type IV collagen protein expression, assessed by Western blotting, in mouse mesangial cells exposed to high glucose (HG) with or without
mMCP-1, CCR2 siRNA, or RS102895 (n  5). The protein expression of fibronectin was 2.1-fold higher in mesangial cells cultured under HG conditions than
in normal glucose (NG) cells, and this increase in fibronectin expression was abrogated in mMCP-1-transfected cells, CCR2 siRNA-transfected cells, and
RS102895-treated cells. *P  0.05 vs. other groups.
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Cruz, CA). The membrane was then washed once for 15 min and
twice for 5 min in 1 PBS with 0.1% Tween 20. Next, the membrane
was incubated in buffer A containing a 1:1,000 dilution of horseradish
peroxidase-linked goat anti-rabbit or anti-mouse IgG (Santa Cruz
Biotechnology). The washes were repeated, and the membrane was
developed with a chemiluminescent agent (ECL; Amersham Life
Science, Arlington Heights, IL). The band densities were measured
using TINA image software (Raytest, Straubenhardt, Germany), and
the changes in the OD of treated cells relative to NG cells were used
for analysis.
Statistical analysis. All values are expressed as means 	 SE.
Statistical analysis was performed using the statistical package SPSS
for Windows Ver. 11.0 (SPSS, Chicago, IL). Results were analyzed
using the Kruskal-Wallis nonparametric test for multiple comparisons.
Significant differences by the Kruskal-Wallis test were further con-
firmed by the Mann-Whitney U-test. P values 0.05 were considered
statistically significant.
RESULTS
MCP-1 and CCR2 levels in mMCP-1 and CCR2 siRNA-
transfected MCs. The levels of mouse and human MCP-1 were
measured in transfected MCs with different concentrations of
mMCP-1 (0.5 or 1 g/ml) to evaluate transfection efficiency.
Human MCP-1 levels were significantly increased in mMCP-1-
transfected MCs in a dose-dependent manner (P  0.0001)
(Fig. 1A), while there was no difference in the levels of mouse
MCP-1 (Fig. 1B). Transfection of the empty vector did not
affect the levels of mouse or human MCP-1.
Next, the efficacy of CCR2 siRNA transfection was evalu-
ated by determining the protein expression of CCR2. As shown
in Fig. 2, CCR2 protein expression was significantly decreased
in CCR2 siRNA-transfected MCs in a dose-dependent manner
Fig. 3.—Continued
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(P  0.05). In contrast, a negative control of the CCR2 siRNA
had no effects on the expression of CCR2 protein.
The concentrations of mMCP-1 (0.5 and 1 g/ml), CCR2
siRNA (10 and 50 nM), and RS102895 (1 and 10 M) used in
this study did not affect cell viability, which was assessed by
an MTT assay (data not shown).
MCP-1/CCR2 inhibition ameliorates HG-induced fibronec-
tin and type IV collagen expression. To clarify whether the
MCP-1/CCR2 system is involved in HG-induced ECM protein
expression, we first examined the effects of MCP-1 on fi-
bronectin and type IV collagen protein expression in MCs. The
administration of 10 ng/ml MCP-1 significantly increased the
protein expression of fibronectin and type IV collagen in
cultured MCs (P  0.05), and this increase in ECM protein
expression was significantly ameliorated by the inhibition of
CCR2 with 10 nM CCR2 siRNA and 10M RS102895 (Fig. 3A),
suggesting that MCP-1 directly induced fibronectin and type IV
collagen expression in MCs via CCR2. Next, we evaluated the
role of the MCP-1/CCR2 system in HG-induced fibronectin and
type IV collagen expression. The protein expression of fibronectin
and type IV collagen were 2.1- and 2.0-fold, respectively, higher
in MCs cultured under HG conditions relative to NG cells (P 
0.05), and this HG-induced ECM protein expression was abro-
gated in mMCP-1-transfected MCs (Fig. 3B) and in CCR2
siRNA-transfected MCs (Fig. 3C). Treatment with 1 and 10 M
RS102895 also significantly inhibited fibronectin and type IV
collagen protein expression in HG-stimulated MCs (P  0.05)
(Fig. 3D).
MCP-1/CCR2 inhibition ameliorates HG-induced TGF-1
levels. Since TGF-1 is the most well-known profibrogenic
cytokine and its expression is increased under diabetic condi-
tions, we attempted to elucidate whether the MCP-1/CCR2
system was involved in HG-induced TGF-1 levels. First, the
direct effects of MCP-1 on TGF-1 levels were examined. The
administration of 10 ng/ml MCP-1 in MCs significantly in-
creased the levels of TGF-1 in conditioned media (P  0.05),
and this increase in TGF-1 concentrations was significantly
abrogated by the inhibition of CCR2 with 10 nM CCR2 siRNA
or 10 M RS102895 (Fig. 4A), suggesting that MCP-1 directly
induced TGF-1 levels in MCs via CCR2. Next, we evaluated
the role of the MCP-1/CCR2 system in HG-induced TGF-1
levels. Compared with MCs exposed to NG, the concentra-
tions of TGF-1 in conditioned media was significantly
increased in HG-stimulated MCs (2,068 	 104 vs. 2,955 	
239 pg/106 cells, P  0.05), and this increase in TGF-1
levels was significantly attenuated by the administration of
0.5 g/ml mMCP-1, 10 nM CCR2 siRNA, and 10 M
RS102895 (Fig. 4B).
MCP-1/CCR2 inhibition ameliorates TGF-1-induced fi-
bronectin and type IV collagen expression. The administration
of 2 ng/ml TGF-1 significantly increased the protein expres-
sion of fibronectin and type IV collagen in cultured MCs (P 
0.05), which was significantly abrogated by the inhibition of
the MCP-1/CCR2 system with 0.5 g/ml mMCP-1, 10 nM
CCR2 siRNA, and 10 M RS102895 (P  0.05) (Fig. 5).
MCP-1 and TGF-1 do not exert an additive effect on
fibronectin and type IV collagen expression. The administra-
tion of 10 ng/ml MCP-1 or 2 ng/ml TGF-1 significantly
increased fibronectin and type IV collagen expression in cul-
tured MCs (P  0.05), but the addition of TGF-1 to MCP-1
did not show any additive or synergistic effect on ECM protein
expression (Fig. 6).
TGF-1 inhibition ameliorates HG-induced MCP-1 levels.
The levels of MCP-1 in HG-conditioned media were signifi-
cantly increased by 142.6% compared with NG media, and this
increase in MCP-1 levels was significantly abrogated by treat-
ment with a TGF-1-neutralizing antibody (P  0.05) (Fig. 7).
TGF-1 inhibition ameliorates MCP-1-induced fibronectin
and type IV collagen expression. The administration of 10
ng/ml MCP-1 significantly increased the protein expression of
fibronectin and type IV collagen in cultured MCs (P  0.05),
and this increase in ECM protein expression was significantly
abrogated by treatment with a TGF-1-neutralizing antibody
(P  0.05) (Fig. 8).
DISCUSSION
A recent study has provided evidence that MCP-1 is directly
involved in ECM synthesis using a mouse model of experi-
mental diabetic nephropathy and cultured human MCs (11).
However, the role of the MCP-1/CCR2 system in high glucose-
induced fibronectin and type IV collagen expression has never
been explored. In this study, we demonstrate for the first time
that the MCP-1/CCR2 system plays an important role in high
glucose-induced fibronectin and type IV collagen synthesis in
cultured MCs. In addition, the results of the present study
Fig. 4. A: transforming growth factor (TGF)-1 concentrations, assessed by
ELISA, in conditioned media of mouse mesangial cells exposed to 10 ng/ml
MCP-1. Administration of 10 ng/ml MCP-1 in mesangial cells significantly
increased the levels of TGF-1 in conditioned media, and this increase in
TGF-1 levels was significantly abrogated by the inhibition of CCR2 with 10
nM CCR2 siRNA (siRNA) or 10 M RS102895 (RS). *P  0.05 vs. other
groups. B: TGF-1 concentrations, assessed by ELISA, in conditioned media
of mouse mesangial cells exposed to high glucose (HG) with or without
mMCP-1, CCR2 siRNA, or RS102895 (n 5). The concentrations of TGF-1
in conditioned media were significantly increased in HG-stimulated mesangial
cells compared with those of NG cells, and this increase in TGF-1 levels was
significantly attenuated by 0.5 g/ml mMCP-1 (Mu), 10 nM CCR2 siRNA
(siRNA), and 10 M RS102895 (RS). *P  0.05 vs. other groups.
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show that the MCP-1/CCR2 system and TGF-1 pathway
are involved in ECM protein expression in high glucose-
stimulated MCs and are regulated by each other.
Previous clinical and experimental studies have suggested
that MCP-1 plays an important role in the pathogenesis of
diabetic nephropathy through the recruitment and activation of
monocytes/macrophages (1, 5, 20, 34), which are known to
release lysosomal enzymes, nitric oxide, and TGF-1 and, in
turn, modify MC biology (24, 39). Since MCs are known to
secrete MCP-1, many studies have focused on the expression
of MCP-1 in MCs under diabetic conditions. High glucose and
advanced glycation end products increased MCP-1 expression
in cultured MCs (15, 37). ANG II, an important mediator in the
pathogenesis of diabetic nephropathy, also stimulated MCP-1
expression in MCs (27). In addition, mechanical stretch, an
in vitro model of glomerular hypertension, induced MCP-1
expression in MCs, and this increase of MCP-1 expression was
ameliorated by an NF-
B inhibitor and rosiglitazone (12). In
this study, the levels of MCP-1 were increased in high glucose-
stimulated MCs, which was in accordance with the results of
the aforementioned studies. Moreover, we demonstrated for the
first time that the increase in MCP-1 levels might directly
induce fibronectin and type IV collagen expression in MCs
under diabetic conditions in an autocrine manner, which was in
addition to the previously known direct proinflammatory ef-
fects of MCP-1 in MCs and tubular epithelial cells.
To inhibit the MCP-1/CCR2 system, three different methods
were used in the present study. First, we used mMCP-1, an
NH2-terminal deletion mutant of the human MCP-1 gene
(7ND). An in vivo study by Furuichi et al. (8) demonstrated
that gene therapy using this mMCP-1 prevented macrophage
infiltration and acute tubular necrosis in mice with renal ische-
mia-reperfusion injury. Administration of mMCP-1 also abro-
gated the infiltration of inflammatory cells and ECM accumu-
lation in animals with renal fibrosis induced by protein over-
load (32) and unilateral ureteral obstruction (UUO) (33). The
results of this study showed that fibronectin and type IV
collagen expression was significantly decreased in mMCP-1-
transfected cells exposed to high glucose, providing strong evi-
dence that MCP-1 was directly involved in high glucose-induced
ECM production. Second, CCR2 siRNA and RS102895, which is
a specific chemical inhibitor of CCR2 and does not affect
chemotaxis or postreceptor signaling of any kind, were used.
MCP-1 is known to induce functional responses through dimer-
ization with CCR2, a G protein-coupled receptor (25). Previous
studies have revealed that inflammatory cell infiltration is signif-
icantly reduced in CCR2-deficient mice with renal injury induced
by ischemia-reperfusion (7), UUO (18), and immune complex
(21), suggesting that MCP-1 exerts its proinflammatory action via
CCR2. The administration of RS102895 prevented renal injury
induced by ischemia-reperfusion (7) and UUO (18), similar to the
results of the experiments with CCR2 knockout mice. In the
present study, there were also significant decreases in fibronectin
and type IV collagen expression in high glucose-stimulated CCR2
siRNA-transfected MCs and in high glucose-stimulated MCs
treated with RS102895, suggesting that MCP-1 mediated ECM
protein expression under diabetic conditions via CCR2. On the
other hand, two alternatively spliced forms of CCR2, CCR2A and
Fig. 5. Fibronectin and type IV collagen protein expression, assessed by Western blotting, in mouse mesangial cells exposed to TGF-1 with or without
mMCP-1, CCR2 siRNA, or RS102895 (n  5). Administration of 2 ng/ml TGF-1 significantly increased the protein expression of fibronectin and type IV
collagen in cultured mesangial cells, and these increases in fibronectin expression and type IV collagen were significantly abrogated by the inhibition of
MCP-1/CCR2 system with 0.5 g/ml mMCP-1 (Mu), 10 nM CCR2 siRNA (siRNA), and 10 M RS102895 (RS). *P  0.05 vs. other groups.
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CCR2B, have been identified in humans (3). In addition, previous
studies have demonstrated that functional differences exist be-
tween the two isoforms and that the two isoforms are expressed by
different cell subsets in idiopathic inflammatory myopathies (2,
28). Based on these findings, there is a possibility that CCR2A
and CCR2B may have a different role in the pathogenesis of
human diabetic nephropathy, but we could not verify it because
mouse MCs were used in this study.
TGF-1 is a well-known mediator of ECM accumulation in
diabetic nephropathy (14). Indeed, previous studies have shown
that there may be an intrinsic regulatory loop between MCP-1 and
TGF-1 in resident glomerular cells (30, 36). Schneider et al. (30)
demonstrated that the increases in type IV collagen and TGF-1
mRNA and protein expression in glomeruli isolated from rats with
experimental glomerulonephritis were abrogated by the neutral-
ization of MCP-1. In another study, the increase in glomerular
TGF-1 expression in a model of glomerular immune injury was
also inhibited by the administration of anti-MCP-1 antiserum in
the isolated, perfused kidney, which was performed to minimize
infiltrating inflammatory cells (36). Moreover, a recent study by
Giunti et al. (11) revealed that MCP-1 directly increased
fibronectin production and TGF-1 levels in cultured MCs
and that the increase in fibronectin levels was abrogated by
an anti-TGF-1-blocking antibody. These findings suggest
that MCP-1 may have a direct profibrogenic effect through
TGF-1 induction. In this study, we also found that MCP-1
induced fibronectin and type IV collagen expression. How-
ever, addition of TGF-1 did not exert any additive or
synergistic effect on MCP-1-induced ECM protein expres-
sion, suggesting that MCP-1 and TGF-1 are closely inter-
related in ECM synthesis. In addition, the results of this
study showed for the first time that the MCP-1/CCR2 system
mediated high glucose-induced TGF-1 expression.
Furthermore, TGF-1 is known to modulate MCP-1 expres-
sion in various cells. TGF-1 induced MCP-1 mRNA and
Fig. 6. Fibronectin and type IV collagen protein expression, assessed by Western blotting, in mouse mesangial cells exposed to MCP-1 and/or TGF-1 (n 
5). Administration of 10 ng/ml MCP-1 or 2 ng/ml TGF-1 significantly increased fibronectin and type IV collagen expression in cultured mesangial cells (P 
0.05), but the addition of TGF-1 to MCP-1 did not show any additive or synergistic effect on ECM protein expression *P  0.05 vs. control.
Fig. 7. MCP-1 levels, assessed by ELISA, in conditioned media of mouse
mesangial cells exposed to HG with or without a TGF-1-neutralizing anti-
body (n  5). The levels of MCP-1 in HG-conditioned media were signifi-
cantly increased compared with those in NG media, and this increase in MCP-1
levels was significantly abrogated by treatment with a TGF-1-neutralizing
antibody. *P  0.05 vs. other groups.
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protein expression in human synovial cells via the extracellular
signal-regulated kinase pathway (38), while Pneumocystis
stimulated MCP-1 production by alveolar epithelial cells
through a c-Jun NH2-amino terminal kinase-dependent mech-
anism (35). MCP-1 expression was also increased in proximal
tubular cells and MCs by TGF-1 (19, 23). Meanwhile, the
administration of an anti-TGF-1 antibody in the isolated,
perfused rat kidney in the absence of infiltrating inflammatory
cells aggravated the increase in glomerular MCP-1 in experi-
mental glomerulonephritis (36). Although the reasons for these
discrepant effects of TGF-1 on MCP-1 expression remain
unclear, differences in experimental conditions (in vitro vs.
in vivo) may contribute. The present study revealed an increase
in MCP-1 expression by TGF-1, which was consistent with
the previous MC studies. In addition, TGF-1-induced fi-
bronectin and type IV collagen expression was mediated by the
MCP-1/CCR2 system and MCP-1-induced ECM production
was mediated by TGF-1. Taken together, we propose that a
close interaction between the MCP-1/CCR2 system and
TGF-1 may contribute to increased ECM synthesis in MCs
under diabetic conditions.
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